Physician profile
Leon Tsai
NPI 1912983883
$6,860.93
in general payments reported to CMS, 2019-2025
31 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $778 · 2021: $1,308 · 2022: $1,532 · 2023: $1,057 · 2024: $1,175 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,486.08 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $484.37 | 2019-2024 | Eohilia, Entyvio |
| Celgene Corporation | $414.10 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $301.78 | 2021-2023 | |
| Janssen Biotech, INC. | $299.08 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.48 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $278.92 | 2020-2025 | |
| Pfizer INC. | $259.81 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $223.34 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $188.92 | 2020-2024 | Rebyota |
| Qol Medical, LLC | $165.06 | 2019-2024 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $155.13 | 2020-2024 | Linzess |
| Genzyme Corporation | $151.98 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $134.35 | 2022-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $115.35 | 2019-2020 | |
| Redhill Biopharma INC. | $113.04 | 2020-2023 | |
| Ardelyx, INC. | $111.84 | 2022-2025 | Ibsrela |
| Ucb, INC. | $110.22 | 2019-2020 | |
| Braintree Laboratories, INC. | $110.07 | 2021-2022 | |
| Boston Scientific Corporation | $54.55 | 2022 | |
| Medtronic, INC. | $48.43 | 2021-2022 | |
| Celltrion USA INC. | $45.40 | 2024 | Zymfentra |
| Biocon Biologics INC | $43.03 | 2024-2025 | Hulio, Yesintek |
| Phathom Pharmaceuticals, INC. | $37.06 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $24.78 | 2022 | |
| Biocompatibles, INC. | $21.70 | 2019 | |
| Lilly USA, LLC | $19.00 | 2024 | Omvoh |
| Amgen INC. | $18.31 | 2023 | Avsola, Amjevita |
| Alfasigma USA, INC. | $14.38 | 2020 | |
| Evoke Pharma, INC. | $14.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.